The effect of synthetic ceramide analogues on gastritis and esophagitis in rats

Arch Pharm Res. 2016 Sep;39(9):1313-23. doi: 10.1007/s12272-016-0792-y. Epub 2016 Jul 8.

Abstract

The effects of ceremide analogues on esophagitis and gastritis in rats were examined. Gastritis induced by indomethacin was significantly reduced after CY3325 and CY3723 treatment, whereas other analogues had no effect. The amount of malondialdehyde in gastritis was significantly reduced by CY3325 or CY 3723. CY3325 or CY 3723 decreased the glutathione levels in gastritis. The myeloperoxidase level in gastritis is increased, and its increment was decreased by CY3325 and CY3723. In reflux esophagitis, the ulceration was decreased by CY3325, CY3723. The gastric volume and acid output are reduced, whereas the pH value is increased by CY3325 or CY3723 after esophagitis. These results suggest that ceramide analogues, CY3325 and CY3723, can prevent the development of gastritis and reflux esophagitis in rats.

MeSH terms

  • Animals
  • Ceramides / chemistry*
  • Ceramides / therapeutic use*
  • Dose-Response Relationship, Drug
  • Esophagitis / drug therapy*
  • Esophagitis / pathology
  • Gastritis / drug therapy*
  • Gastritis / pathology
  • Male
  • Rats
  • Rats, Sprague-Dawley
  • Treatment Outcome

Substances

  • Ceramides